The safety and efficacy of Quetiapine during human pregnancy have not yet been established. Following pregnancies in which Quetiapine was used, neonatal withdrawal symptoms were observed. Therefore, Quetiapine should only be used during pregnancy if the benefits justify the potential risks.
There have been published reports of Quetiapine excretion into human breast milk; however the degree of excretion was not consistent. Women who are breast-feeding should therefore be advised to avoid breast-feeding while taking Quetiapine.
Neonates exposed to antipsychotics (including Quetiapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.